Loading clinical trials...

Predictors of Response to Treatment for Depression | Clinical Trials | Clareo Health

COMPLETEDNA

Predictors of Response to Treatment for Depression

Neural Predictors of Response to Cognitive Behavioral Therapy for Adolescent Depression

NCT03154008•Vanderbilt University Medical Center

Summary

The current study will examine neurophysiological, specifically event-related potential (ERP), measures of emotional processing as predictors of response to cognitive behavior therapy for adolescent depression.

Detailed Description

Neurophysiological measures (i.e., event-related potentials) of reward responsiveness and regulation of mood-congruent, sad stimuli will be assessed in a sample of adolescents with depression prior to group cognitive behavior therapy (CBT). CBT will follow the Adolescent Coping with Depression Course, an established 16-session group treatment protocol, and consist of behavioral activation, relaxation skills, cognitive therapy, social skills, problem solving, and relapse prevention. Changes in symptoms will be monitored through biweekly self-report and clinician ratings to examine prediction of change in symptoms across CBT. Baseline individual differences in reward responsiveness and emotion regulation will be evaluated as predictors of change in self-reported symptoms and clinician-rated improvement following CBT.

Eligibility

Age

14 - 18 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Participants presenting with major depressive or persistent depressive disorder and moderate severity on the Clinical Global Impressions scale.
•Participants may have comorbid externalizing or anxiety disorders.
•Participants (and parents of minors) fluent in English.

Exclusion Criteria

•Youth with history of treatment for substance use disorders.
•Youth with intellectual or developmental disabilities (e.g., autism spectrum disorders, pervasive developmental disorders).
•Youth with lifetime schizophrenia, psychosis, or mania.
•Youth with severe current suicidality.
•Youth taking antipsychotic medications or mood stabilizers.
•Youth with recent changes in dosage of antidepressant (adolescents with change in dosage in past 30 days who otherwise meet study criteria will be asked to begin the study once dosage has been stable for 30 days).
•Parent or child not fluent in English.
•Youth who are unable to complete study procedures because of visual or hearing impairments.
•Youth who have recently started outside therapy (past 30 days at time of intake), are engaged in treatment that is determined to be too similar to study therapy (e.g, other CBT groups), or are currently in treatment that is too intensive to allow for participation in study therapy (e.g., partial hospitalization programs)

Locations (1)

Vanderbilt University

Nashville, Tennessee, United States

Key Dates

Start Date

June 1, 2017

Primary Completion Date

June 8, 2020

Completion Date

June 8, 2020

Last Updated

July 23, 2020

Enrollment

ACTUAL participants

Conditions

Adolescent DepressionDepression

Interventions

Cognitive Behavioral Therapy

BEHAVIORAL

ACT Together: Implementing a Web-Based Program With Brief Coaching for Parents of Children With Disabilities in Pediatric Outpatient Clinics

NCT07360600

ParentsChildren With Disabilities+2 more

View study

RECRUITINGPHASE3

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

NCT06793397

Major Depressive Disorder (MDD)Depression in Adults+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 23, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Predictors of Response to Treatment for Depression

Inclusion Criteria

Exclusion Criteria

ACT Together: Implementing a Web-Based Program With Brief Coaching for Parents of Children With Disabilities in Pediatric Outpatient Clinics

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

Readiness and Progress in Emotion Regulation Therapy

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression

Serotonin-norepinephrine Reuptake Inhibitor in Prophylaxis of Depression Following Fragility Fractures